





Section 8 – Other Events

Item 8.01 Other Events.

On January 10, 2019, Miragen Therapeutics, Inc., a Delaware corporation, issued a press release announcing data from its Phase 1 clinical trial evaluating cobomarsen, a microRNA-155 inhibitor, in patients with cutaneous T-cell lymphoma (CTCL) and in adult T-cell lymphoma/leukemia (ATLL), as well as initial data from a Phase 1 clinical trial of cobomarsen in patients with diffuse large B-cell lymphoma (DLBCL). A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Section 9 – Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Exhibit Description
-------------------	---------------------

99.1	<u>Press release, dated January 10, 2019</u>
------	--

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Miragen Therapeutics, Inc.

Date: January 10, 2019

By: /s/ Jason A. Leverone  
Jason A. Leverone  
Chief Financial Officer